New Research Links Type 1 Diabetes and Multiple Sclerosis Through Shared Immune Targets

Type 1 diabetes and multiple sclerosis are both autoimmune conditions—diseases in which the immune system mistakenly attacks the body's own tissues. While these are typically considered separate diseases, researchers have long observed that people with Type 1 diabetes face a higher-than-average risk of developing MS, and vice versa. Until now, the reason for this connection has been unclear.

A new study published in *Cells* suggests that the answer may lie in a protein called myelin basic protein, or MBP. MBP is essential for maintaining the insulation around nerve fibers—similar to the protective coating around electrical wires. When the immune system attacks MBP, it can damage this insulation, leading to nerve problems in both conditions.

Researchers used multiple laboratory techniques to test whether immune components from Type 1 diabetes patients could recognize MBP as a target. They tested antibodies (immune proteins) that attack three key diabetes-related antigens: insulin, PTPRN (also called IA-2), and GAD1. All three of these antibodies were found to cross-react with MBP, meaning they could bind to and potentially attack this nerve-insulation protein.

The team also examined T-cell receptors—the immune cells that directly identify and destroy targets. Using genetic analysis, they found that T-cell receptors from Type 1 diabetes patients predominantly recognized MBP as an antigen. In addition, blood serum from Type 1 diabetes patients reacted with MBP, whereas serum from healthy individuals did not.

Perhaps most strikingly, genetic analysis revealed that some T-cell receptors from Type 1 diabetes patients and multiple sclerosis patients were nearly identical, suggesting both conditions may involve the same immune targets.

One of the most common complications of Type 1 diabetes is neuropathy—damage to the nerves that can cause pain, numbness, or weakness, particularly in the feet and legs. While high blood sugar is known to damage nerves directly, previous research has shown that demyelinization—damage to the myelin insulation—also occurs in diabetic neuropathy.

This new finding suggests that immune cross-reactivity against MBP may contribute to that demyelinization. In other words, the same immune attack that defines Type 1 diabetes may also damage the protective coating around nerves, compounding the nerve damage caused by high blood sugar alone.

This research provides a potential biological explanation for why Type 1 diabetes and multiple sclerosis are linked and why nerve damage in Type 1 diabetes may involve immune attacks on nerve insulation. However, this is an early-stage laboratory study. It identifies associations and cross-reactivity patterns but does not prove that MBP attack is the cause of diabetic neuropathy or MS in any individual patient.

The researchers also noted that while proteins from some bacteria (Clostridia) showed similarity to MBP, coxsackievirus proteins did not—an important clue that some infections may trigger cross-reactive immune responses more easily than others.

Further research will be needed to determine whether targeting MBP-related immune attacks could help prevent or treat neuropathy in Type 1 diabetes or reduce the risk of MS in people with diabetes. For now, this work opens a new door to understanding how these two autoimmune conditions are connected.

Source: Cells. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.